Synlogic Reminds Stockholders of 2021 Annual General Meeting Details
Synlogic, Inc. (Nasdaq: SYBX) has announced its 2021 Annual General Meeting of Stockholders will occur on June 10, 2021, at 9:00 am ET, via virtual format.
Stockholders of record as of April 13, 2021, can access the meeting through this link starting at 8:45 am ET. Synlogic encourages stockholders to vote and submit proxies beforehand. The company focuses on developing Synthetic Biotic medicines for metabolic disorders and has a proprietary pipeline targeting additional diseases.
- Scheduled Annual Meeting for stockholders shows transparency and commitment to management.
- Focus on Synthetic Biotic medicines presents potential for growth in metabolic disorder treatments.
- Forward-looking statements carry risks, including uncertainties in clinical development and potential delays.
CAMBRIDGE, Mass., June 3, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reminds stockholders that it will hold its 2021 Annual General Meeting of Stockholders on June 10, 2021 at 9:00 am ET. The Annual Meeting will be held in virtual format only via live audio webcast.
Synlogic's stockholders of record as of April 13, 2021 (the "Record Date"), can attend and vote at the Annual Meeting by accessing the meeting center at www.virtualshareholdermeeting.com/SYBX2021 and entering the control number on the proxy card or Notice of Internet Availability of Proxy Materials previously received. Instructions on how to connect to the Annual Meeting and participate via the Internet are also posted at www.virtualshareholdermeeting.com/SYBX2021. Online access to the Annual Meeting will begin at 8:45 am ET. Stockholders should allow ample time for the check-in procedures.
Whether or not stockholders plan to virtually attend the Annual Meeting, Synlogic urges them to vote and submit their proxy in advance of the Annual Meeting by one of the methods described in the proxy materials for the Annual Meeting.
About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The company is also building a portfolio of partner-able assets in immunology and oncology.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of SYNB1891 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
View original content:http://www.prnewswire.com/news-releases/synlogic-reminds-stockholders-of-2021-annual-general-meeting-details-301305076.html
SOURCE Synlogic, Inc.
FAQ
When is Synlogic's 2021 Annual General Meeting?
How can stockholders participate in the Synlogic Annual Meeting?
What is the purpose of Synlogic's Annual General Meeting?
What date is the record for Synlogic stockholders to vote?
What is Synlogic's focus in drug development?
